다우존스 지수

무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.

등록

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

The securities to be sold were acquired upon the vesting of previously exercised stock options on 06/01/2012 through 05/11/2016

Date of Notice

09/18/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

06/10/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Andrea M.A. Pfeifer

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

AC Immune (NASDAQ:ACIU)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025

AC Immune 차트를 더 보려면 여기를 클릭.

AC Immune (NASDAQ:ACIU)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025

AC Immune 차트를 더 보려면 여기를 클릭.

AC Immune SA News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
0년 19월 12일, 2024 (1 월 전) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
0년 14월 12일, 2024 (1 월 전) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
0년 10월 12일, 2024 (1 월 전) • Edgar (US Regulatory)

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
0년 10월 12일, 2024 (1 월 전) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
0년 14월 11일, 2024 (2 월 전) • Edgar (US Regulatory)

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
0년 14월 11일, 2024 (2 월 전) • GlobeNewswire Inc.

AC Immune to Present at the Jefferies 2024 London Healthcare Conference
0년 13월 11일, 2024 (2 월 전) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
0년 5월 11일, 2024 (3 월 전) • Edgar (US Regulatory)

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
0년 5월 11일, 2024 (3 월 전) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
0년 28월 9일, 2024 (4 월 전) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
0년 20월 9일, 2024 (4 월 전) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
0년 19월 9일, 2024 (4 월 전) • Edgar (US Regulatory)

More AC Immune SA News Articles

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관